Insulet investors face August 31, 2026 lead plaintiff deadline in class action
Rosen Law Firm said the securities suit covers Insulet investors from February 21, 2025 to May 26, 2026 and alleges undisclosed manufacturing-control defects tied to 2026 Omnipod Medical Device Corrections.
Investors who bought Insulet Corporation securities between February 21, 2025 and May 26, 2026 have until August 31, 2026 to seek appointment as lead plaintiff in a putative securities class action, according to Rosen Law Firm. The filed lawsuit alleges Insulet failed to disclose defective manufacturing controls and procedures, creating heightened product safety and regulatory risks. The claims focus on two 2026 disclosures: a March 12 voluntary Medical Device Correction for certain Omnipod 5 Pods and a May 26 voluntary Medical Device Correction affecting certain lots of Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System, or Omnipod Eros, Pods due to a manufacturing issue that could cause insulin under-delivery. Insulet shares fell 6.9% to $219.84 on March 13, 2026 and 5.1% to $146.01 on May 27, 2026 after those disclosures. Rosen said investors may remain absent class members and that no class has yet been certified.
- lead plaintiff: A representative party who acts on behalf of other class members in directing the litigation.
- class action: A lawsuit brought by one or more plaintiffs on behalf of a larger group with similar claims.
- Medical Device Correction: An action taken to address a problem with a medical device already in distribution.